Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
LuCAB: Cabazitaxel + 177Lu-PSMA-617 in mCRPC
NCT05340374Phase 2Active, not recruiting
- Sponsor
- Peter MacCallum Cancer Centre
- Start
- Jul 2022
- Primary completion
- Jun 2026
- Modality
- Allosteric Modulators, Peptide-Drug Conjugates
- Countries
- 1
01
Overview
A Phase 2 trial of cabazitaxel, lutetium lu 177 vipivotide tetraxetan in metastatic castration-resistant prostate cancer (mCRPC), sponsored by Peter MacCallum Cancer Centre. Started Jul 2022; status: active, not recruiting.
02
Drugs
cabazitaxellutetium lu 177 vipivotide tetraxetan
03
Conditions
metastatic castration-resistant prostate cancer (mCRPC)
Beyond the preview
Go deeper on NCT05340374.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05340374.